Processing the protocol with id 136
##########################################
Searching for the item "2a Scientific background and explanation of rationale..."
This part was defined, probably, at this section: 4. INTRODUCTION AND RATIONALE 
For more information about the rationales, go to sections:
4.1 Background and Rationale 
I have not found anything about the previous studies from titles, lets take a look for the introduction
Previous studies: FOUND
Occurrences in the text:
12397	clinical experience	"... (17).    Overall, none of these clinical experiences provided..."
##########################################
Searching for the item "2b Specific objectives or hypotheses"...
This part was defined, probably, at this section: 5.  STUDY OBJECTIVES 
For more information about the primary objectives, go to sections:
5.1 Primary 
For more information about the secondary objectives, go to sections:
5.2 Secondary 
Objectives: FOUND
Occurrences in the text:
32681	evaluate 	"... s to evaluate xaliproden in preventing oxaliplatin induced  cumulative PSN in patients treated with..."
33658	evaluate 	"...   To evaluate for each treatment arm:     Neurotoxicity:   Duration of oxaliplatin induced PSN,  ..."
33066	compare 	"...   To compare the risk of occurrence of severe oxaliplatin induced cumulative PSN  (Grade  dose   of..."
33395	compare 	"...   To compare the Response Rate (RR) between the control arm A and the experimental arm  B in order to..."
##########################################
Searching for the item "3a Description of trial design (such as parallel, factorial) including allocation ratio"...
This part was defined, probably, at this section: 6. STUDY DESIGN 
I found the following features of the study:
placebo controlled
randomized
2 arm
Phase III
multicenter
Placebo: found -> randomized-controlled study
Occurrences in the text:
34424	placebo	 "... multicenter, randomized, placebo controlled, 2 arm..."
34493	placebo	 "...  of xaliproden or matching placebo (i.e. study drugs) in..."
35187	placebo	 "... 1mg daily, or matching placebo will be initiated at..."
Allocation ratio: NOT FOUND
##########################################
Checking for the item "4a Eligibility criteria for participants..."
This part was defined, probably, at this section: 7. SELECTION OF PATIENTS 
I have found: exclusion criteria, inclusion criteria
##########################################
Checking for the item "5 Interventions for each group with sufficient details to allow replication, including how and when they were actually administered"
This part was defined, probably, at this section: 8. TREATMENTS 
Maybe, these sections will be interested for you:
8.1.1.4 Duration of treatment 
8.1.1.7 Packaging and labeling 
8.1.3 Guidelines for Treatment Modifications 
8.1.3.2.1 Dosing delays 
8.2 Concomitant treatments 
8.2.1 Prohibited treatments 
8.2.2 Permitted concomitant treatments 
##########################################
Checking for the item “7a how sample size was determined”...
This part was defined, probably, at this section: 13.2 Determination of sample size 
##########################################
Searching any information about a randomzation
This part was defined, probably, at this section: 8.1.1.9 Access to randomization code during the study 
Maybe this information will be interesting:
46168	randomization will be stratified	"... y.  In order to balance treatments groups with regard to prognostic factors for colorectal  cancer, randomization will be stratified by using a centralized randomization service  (Interactive Voice..."
36365	will be randomized	"... trate a 40% reduction in the risk of occurrence of Grade 3  4 cumulative PSN.  Overall 900 patients will be randomized. Accrual is planned to last 2 years. Sixty to 100  investigational sites are..."
##########################################
Checking for the item “11a  if done, who was blinded after assignment to interventions (eg, participants, care providers, those assessing outcomes) and how.”
This part was defined, probably, at this section: 8.1.1.5 Description of the blinding methods 
This part was defined, probably, at this section: 8.1.1.9 Access to randomization code during the study 
This part was defined, probably, at this section: 15. STUDY MONITORING 
##########################################
Checking for the item “12a  statistical methods used to compare groups for primary and secondary outcomes”
This part was defined, probably, at this section: 13. STATISTICAL CONSIDERATIONS 
This part was defined, probably, at this section: 13.4 Data analysis considerations 
This part was defined, probably, at this section: 13.7.2.2 Statistical analysis of secondary variables 
I found the following methods:
112536 	 log rank 	 "...  two treatments  groups using a 2 sided log rank test using a type I error of..."
113008 	  cox  	 "...  Other analyses for primary variable(s)  Cox proportional hazard modeling..."
104459 	 kaplan meier 	 "... tion of cumulative dose of oxaliplatin (Kaplan Meier method).    The sample..."
112452 	 kaplan meier 	 "... xaliplatin will be  estimated using the Kaplan Meier method and compared..."
112583 	 kaplan meier 	 "... k test using a type I error of 0.05.    Kaplan Meier curves for each of the two..."
115865 	 kaplan meier 	 "... ith median and 95% CI, estimated by the Kaplan Meier  method. Kaplan Meier..."
115887 	 kaplan meier 	 "...  estimated by the Kaplan Meier  method. Kaplan Meier Curves will be also..."
116285 	 kaplan meier 	 "... f cumulative PSN will be analyzed using Kaplan Meier  method.    13.8 Safety..."
176114 	 kaplan meier 	 "... ulative PSN will be  analyzed using the Kaplan Meier method.  Change in NCS..."
176518 	 kaplan meier 	 "... th median and 95% CI, estimated by the  Kaplan Meier method.    Safety..."
177053 	 kaplan meier 	 "... ulative PSN  will be analyzed using the Kaplan Meier method.  Change in NCS..."
177265 	 kaplan meier 	 "... th median and 95% CI, estimated by the  Kaplan Meier method.    Safety..."
229786 	 kaplan meier 	 "... f cumulative PSN will be analyzed using Kaplan Meier  method.  Property of the..."
